The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subj…

Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more

~Estimated

~$10 – $8,750

Neomorph, IncNCT07300241

Phase 2

Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)

Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactiva…

Renal Cell CarcinomaMetastatic Renal Cell CarcinomaKidney Cancer+2 more

~Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03786796